Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study

J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle, J. P. Hallé, I. Hramiak, P. Johnston, M. Davis

Research output: Contribution to journalLetterpeer-review

129 Scopus citations

Fingerprint

Dive into the research topics of 'Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study'. Together they form a unique fingerprint.